Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715910 · ClinicalTrials.gov registry record · Phase 2
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 818
- Enrollment target
NCT00715910: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00715910 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 818 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (515% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715910, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 818 participants
- Enrollment target
Study Summary
In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 and Menactra® in a previous study (whose objectives \& outcome measures are presented in a separate protocol posting with NCT number =00454909) will be evaluated. The safety and immune response to a booster dose of vaccine GSK134612 administered at 5 years post-primary vaccination and a primary vaccination of a newly enrolled group with GSK 134612 vaccine will also be evaluated.
Primary Outcome
hSBA antibody titers were assessed for the hSBA-MenA, hSBA-MenC, hSBA-MenW-135, and hSBA-MenY serogroups respectively. The antibody cut-off value assessed was equal to or above 1:8.
Interventions
- PROCEDURE Blood sampling
- BIOLOGICAL Nimenrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 818 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT00715910 record still lists
NCT00715910 is an interventional study that assigns participants to a tested intervention. The registered 818 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (515% higher).
The record links to 0 conditions, and to 2 interventions - of which Blood sampling is the first listed.
NCT00715910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00715910 about?
NCT00715910 is a clinical study titled "The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults". In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 and Menactra® in a previous study (whose objectives \& outcome measures are presented in a separate proto...
What is the current status of trial NCT00715910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 818 participants. The study started on 2008-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00715910?
The interventions under investigation include: Blood sampling (PROCEDURE), Nimenrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00715910?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00715910's enrollment target sits among peer trials
818 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia